These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 7689451)
1. Postmarketing surveillance of quinolones, 1990 to 1992. Davey P; McDonald T Drugs; 1993; 45 Suppl 3():46-53. PubMed ID: 7689451 [TBL] [Abstract][Full Text] [Related]
2. Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: experience from large cohorts from the Drug Safety Research Unit Prescription-Event Monitoring database. Clark DW; Layton D; Wilton LV; Pearce GL; Shakir SA Drug Saf; 2001; 24(15):1143-54. PubMed ID: 11772147 [TBL] [Abstract][Full Text] [Related]
3. The withdrawal of temafloxacin. Are there implications for other quinolones? Finch RG Drug Saf; 1993 Jan; 8(1):9-11. PubMed ID: 8385956 [No Abstract] [Full Text] [Related]
7. Safety profile of the fluoroquinolones: analysis of adverse drug reactions in relation to prescription data using four regional pharmacovigilance databases in Italy. Lapi F; Tuccori M; Motola D; Pugi A; Vietri M; Montanaro N; Vaccheri A; Leoni O; Cocci A; Leone R; Conforti A; Moretti U; Sessa E; Mazzaglia G; Mugelli A; Mazzei T; Vannacci A Drug Saf; 2010 Sep; 33(9):789-99. PubMed ID: 20701411 [TBL] [Abstract][Full Text] [Related]
9. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Wilton LV; Pearce GL; Mann RD Br J Clin Pharmacol; 1996 Apr; 41(4):277-84. PubMed ID: 8730972 [TBL] [Abstract][Full Text] [Related]
10. Temafloxacin voluntary withdrawal: concerns about multicenter testing and postmarketing surveillance. Rapp RP Ann Pharmacother; 1992; 26(7-8):995. PubMed ID: 1324034 [No Abstract] [Full Text] [Related]
11. Musculoskeletal adverse drug reactions: a review of literature and data from ADR spontaneous reporting databases. Conforti A; Chiamulera C; Moretti U; Colcera S; Fumagalli G; Leone R Curr Drug Saf; 2007 Jan; 2(1):47-63. PubMed ID: 18690950 [TBL] [Abstract][Full Text] [Related]
12. Tolerability of fluoroquinolone antibiotics. Past, present and future. Ball P; Tillotson G Drug Saf; 1995 Dec; 13(6):343-58. PubMed ID: 8652079 [TBL] [Abstract][Full Text] [Related]
13. The safety profile of the fluoroquinolones. Bertino J; Fish D Clin Ther; 2000 Jul; 22(7):798-817; discussion 797. PubMed ID: 10945507 [TBL] [Abstract][Full Text] [Related]
14. Adverse drug reactions with fluoroquinolones. Royer RJ Therapie; 1996; 51(4):414-6. PubMed ID: 8953819 [TBL] [Abstract][Full Text] [Related]
15. Temafloxacin syndrome: review of 95 cases. Blum MD; Graham DJ; McCloskey CA Clin Infect Dis; 1994 Jun; 18(6):946-50. PubMed ID: 8086558 [TBL] [Abstract][Full Text] [Related]
16. Drug-induced anaphylaxis : case/non-case study based on an italian pharmacovigilance database. Leone R; Conforti A; Venegoni M; Motola D; Moretti U; Meneghelli I; Cocci A; Sangiorgi Cellini G; Scotto S; Montanaro N; Velo G Drug Saf; 2005; 28(6):547-56. PubMed ID: 15924506 [TBL] [Abstract][Full Text] [Related]
17. Temafloxacin: a safe antibiotic for the elderly, patients with comorbidities, and other special populations. Pernet AG Am J Med; 1991 Dec; 91(6A):162S-165S. PubMed ID: 1662888 [TBL] [Abstract][Full Text] [Related]